Substitution of chimera 3 tropomyosin for wild-type TPM1 increased myosin S1 actin affinity by an order of magnitude and strengthened myosin S1-ADP binding to actin 2-fold.
Inserting mammalian tropomyosin sequences into yeast tropomyosin induces it to mimic the activating behavior of mammalian tropomyosin, suggesting an allosteric mechanism for myosin-tropomyosin effects on the actin filament.
Tropomyosin is a ubiquitous actin-binding protein with an extended coiled-coil structure. Tropomyosin-actin interactions are weak and loosely specific, but they potently influence myosin. One such influence is inhibitory and is due to tropomyosin's statistically preferred positions on actin that sterically interfere with actin's strong attachment site for myosin. Contrastingly, tropomyosin's other influence is activating. It increases myosin's overall actin affinity ∼4-fold. Stoichiometric considerations cause this activating effect to equate to an ∼4(7)-fold effect of myosin on the actin affinity of tropomyosin. These positive, mutual, myosin-tropomyosin effects are absent if Saccharomyces cerevisiae tropomyosin replaces mammalian tropomyosin. To investigate these phenomena, chimeric tropomyosins were generated in which 38-residue muscle tropomyosin segments replaced a natural duplication within S. cerevisiae tropomyosin TPM1. Two such chimeric tropomyosins were sufficiently folded coiled coils to allow functional study. The two chimeras differed from TPM1 but in opposite ways. Consistent with steric interference, myosin greatly decreased the actin affinity of chimera 7, which contained muscle tropomyosin residues 228-265. On the other hand, myosin S1 increased by an order of magnitude the actin affinity of chimera 3, which contained muscle tropomyosin residues 74-111. Similarly, myosin S1-ADP binding to actin was strengthened 2-fold by substitution of chimera 3 tropomyosin for wild-type TPM1. Thus, a yeast tropomyosin was induced to mimic the activating behavior of mammalian tropomyosin by inserting a mammalian tropomyosin sequence. The data were not consistent with direct tropomyosin-myosin binding. Rather, they suggest an allosteric mechanism, in which myosin and tropomyosin share an effect on the actin filament.
Ali et al. (Mon,) reported a other. Chimeric tropomyosins (chimera 3 and chimera 7) vs. Wild-type TPM1 (Saccharomyces cerevisiae tropomyosin) was evaluated on Actin affinity and myosin S1-ADP binding. Substitution of chimera 3 tropomyosin for wild-type TPM1 increased myosin S1 actin affinity by an order of magnitude and strengthened myosin S1-ADP binding to actin 2-fold.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: